Over 300 Texas Auctions End Today - Bid Now
Over 30 Total Lots Up For Auction at Two Locations - WI 05/27, NV 05/29

James Allison, Padmanee Sharma and Ramy Ibrahim

ImaginAb appoints new members to scientific advisory board
July 09, 2018
Molecular Imaging PET
LOS ANGELES, July 9, 2018 /PRNewswire/ -- ImaginAb Inc., an immuno-oncology imaging company, today announced the appointment of James Allison, Padmanee Sharma and Ramy Ibrahim to its Scientific Advisory Board (SAB) comprised of foremost global key opinion leaders in the development of anticancer therapies.

"We are excited to welcome Jim, Pam and Ramy to our Scientific Advisory Board," said Martyn Coombs, CEO of ImaginAb. "Jim's original work was the basis for the whole immuno-oncology field, and Jim, Pam and Ramy are right at the center of the exciting and rapid developments in immuno-oncology."

These additions build on the recent appointments of Antoni Ribas, Dan Von Hoff and David Mankoff. The SAB will work closely with ImaginAb's management team to advance the development of ImaginAb's CD8 T Cell ImmunoPET, an imaging agent that has the potential to expedite the development of next-generation therapeutics.
stats Advertisement
DOTmed text ad

Training and education based on your needs

Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money

stats
"I look forward to being a part of ImaginAb's SAB," said Dr. Allison. "ImaginAb's plan, which is to visualize T cells directly in patients in order to determine whether patients will respond to immune checkpoint therapy, will be an important step forward for biomarker development in the field of cancer immunotherapy."

"I'm excited to work with the ImaginAb team as they develop novel strategies to image the immune response in patients," said Dr. Sharma. "These types of advances will help us to improve patient selection and development of immunotherapies."

"I look forward to joining ImaginAb's SAB as their platform is very aligned with the Parker Institute's mission to improve the quality of life of cancer patients undergoing immunotherapy," said Dr. Ibrahim. "Data from their Phase 1 study is very encouraging and using a non-invasive technology to replace the need of biopsies holds great promise for patients."

James Allison: Dr. James Allison is the Chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, Director of the Parker Institute for Cancer Immunotherapy, and the Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center. He has spent a distinguished career studying the regulation of T cell responses and developing strategies for cancer immunotherapy. Among his most notable discoveries are the determination of the T cell receptor structure and that CD28 is the major costimulatory molecule that allows full activation of naïve T cells and prevents anergy in T cell clones. His lab resolved a major controversy by demonstrating that CTLA-4 inhibits T-cell activation by opposing CD28-mediated costimulation and that blockade of CTLA-4 could enhance T cell responses, leading to tumor rejection in animal models. This finding paved the wave for the emerging field of immune checkpoint blockade therapy for cancer. Work in his lab led to the development of ipilimumab, an antibody to human CTLA-4 and the first immune checkpoint blockade therapy approved by the FDA. Among many honors, he is a member of the National Academies of Science and Medicine and received the Lasker-Debakey Clinical Medical Research award in 2015. His current work seeks to improve immune checkpoint blockade therapies currently used by our clinicians and identify new targets to unleash the immune system in order to eradicate cancer.

You Must Be Logged In To Post A Comment

 

advertisement

Molecular Imaging Homepage

EXPLORER scanner cuts total-body PET imaging time for cancer detection to 20 minutes
Uses a variation of the Patlak plot — called the relative Patlak plot — to generate high-quality parametric images
OEMs dominate PET/CT service landscape, IMV reports
Among midsized hospitals, OEM support stood at 77%, with 20% in-house and 13% ISO
IBA debuts compact synthesizer for radiopharmaceutical manufacturing
CASSY is designed to integrate into existing lab workflows and optimize space within hot cells
Ratio Therapeutics plans radiopharmaceutical manufacturing site in Salt Lake City
Designed for end-to-end production of radiopharmaceuticals, with an eye toward scaling up for commercial supply
SHINE Technologies to acquire Lantheus’ SPECT division
Deal includes the manufacturing operations at Lantheus’ North Billerica, Massachusetts site
Blue Earth Therapeutics begins phase 2 trial of lutetium-based radioligand for prostate cancer
Assessing efficacy and safety across different dosing regimens
SpectronRx passes FDA inspection with no observations for Indianapolis facility
Plans to expand operations to meet global demand for radiopharmaceuticals
SHINE enters UAE market with Modawina partnership for Lu-177 distribution
Extends presence across the Europe, Middle East, and Africa regions
PET procedure volumes in US rose 12% in 2024
Demand grew alongside limited expansion in installed imaging capacity, according to IMV
SHINE and Sumitomo form partnership to expand radioisotope supply in Asia
The agreement will focus on establishing supply chains for SHINE’s core offerings